MUC5B and idiopathic pulmonary fibrosis: Regarding therapies, the PANTHER-IPF clinical trial2 was conducted in carriers of the aforementioned MUC5B and TOLLIP variants to evaluate their modulatory effect on immunosuppressive and antioxidant treatments.